Differing Administration Time-Dependent Effects of Aspirin on Blood Pressure in Dipper and Non-Dipper Hypertensives
|
|
- Ronald Barton
- 5 years ago
- Views:
Transcription
1 Differing Administration Time-Dependent Effects of Aspirin on Blood Pressure in Dipper and Non-Dipper Hypertensives Ramón C. Hermida, Diana E. Ayala, Carlos Calvo, José E. López, Artemio Mojón, Marta Rodríguez, José R. Fernández Abstract Aspirin is a potent antioxidative agent that reduces vascular production of superoxide, prevents angiotensin II induced hypertension, and induces NO release. Low-dose aspirin administered at bedtime, but not on awakening, has also been shown to reduce blood pressure, possibly enhancing the nocturnal trough in NO production. Because endothelium-dependent vasodilation is blunted through a decrease in NO release in non-dipper compared with dipper patients, we compared the administration time-dependent influence of aspirin on ambulatory blood pressure in dipper and non-dipper hypertensive subjects. We studied 257 patients with mild hypertension (98 men and 159 women), years of age, randomly assigned to receive 100 mg per day of aspirin either on awakening or at bedtime. Ambulatory blood pressure was measured for 48 hours at baseline and after 3 months of intervention. Blood pressure was slightly elevated after aspirin on awakening (increase of 1.5/1.0 mm Hg in the 24-hour mean of systolic/diastolic blood pressure; P 0.028). A highly significant blood pressure reduction was observed in patients who received aspirin at bedtime (decrease of 7.2/4.9 mm Hg in systolic/diastolic blood pressure; P 0.001). The reduction in nocturnal blood pressure mean was double in non-dippers (11.0/7.1 mm Hg) compared with dippers (5.5/3.3 mm Hg; P 0.001). This prospective trial corroborates the significant administration time-dependent effect of low-dose aspirin on blood pressure, mainly in non-dipper hypertensive patients. The timed administration of low-dose aspirin could thus provide a valuable approach, beyond prevention of cardiovascular disease, in the blood pressure control of patients with mild hypertension. (Hypertension. 2005;46[part 2]: ) Key Words: blood pressure monitoring, ambulatory hypertension, mild nitric oxide circadian rhythm Acetylsalicylic acid (ASA; aspirin) is a nonsteroidal anti-inflammatory drug (NSAID) with demonstrated inhibitory effects on cyclooxygenases (COXs) responsible for arachidonic acid metabolism and prostaglandin production. 1 Previous studies have demonstrated that ASA is a potent antioxidative agent that markedly reduces vascular production of superoxide in normotensive and hypertensive rats. 2 In addition, ASA was found to prevent angiotensin II induced hypertension and cardiovascular hypertrophy, mainly through its antioxidative properties in preventing the generation of superoxide. 3 Moreover, recent results have demonstrated that ASA induces NO release from vascular endothelium. 4,5 This effect appears to be attributable to a direct acetylation of the endothelial NO synthase protein. No attention has been paid so far in these studies to potential administration time dependencies in the effects of ASA. However, a significant circadian variation has been demonstrated in several oxidative stress markers, including 8-hydroxydeoxyguanosine, malondialdehyde, and 8-isoprostane. 6 The peak concentrations of the 3 markers occurred early in the evening, with trough values obtained during nocturnal sleep. These peak and trough times are highly correlated with those of serum NO. 6,7 Moreover, among many other variables related to the regulation of blood pressure (BP), a predictable circadian variation has been demonstrated in plasma renin activity, angiotensin II, catecholamines, atrial natriuretic peptides, aldosterone, and angiotensin-converting enzyme. 8 Previous laboratory animal and clinical trial research demonstrates administration time-dependent effects of ASA. Thus, the effects of ASA on lipoperoxides - and -adrenergic receptors and BP in clinically healthy subjects depend on the circadian timing of ASA administration. 9 Moreover, ASA has also been shown to produce an administration time-dependent 30% inhibition of angiotensin II, associated to the documented effects of ASA on plasma renin activity. 10 Most important, the administration time-dependent influence of ASA on BP was demonstrated previously in a randomized trial on healthy women 9 and other independent double-blind, randomized, placebo-controlled clinical trials conducted: first on clinically healthy subjects, 11 a second on normotensive and hypertensive subjects, 12 a third on pregnant women at high risk for preeclampsia, 13 and a fourth in untreated patients with mild hypertension. 14 The findings of Received April 27, 2005; first decision May 12, 2005; revision accepted May 24, From the Bioengineering and Chronobiology Laboratories (R.C.H., D.E.A., A.M., J.R.F.), University of Vigo, Campus Universitario, Spain; and Hypertension and Vascular Risk Unit (C.C., J.E.L., M.R.), Hospital Clínico Universitario, Santiago de Compostela, Spain. Correspondence to Prof Ramón C. Hermida, PhD, Director, Bioengineering and Chronobiology Laboratories, E.T.S.I. Telecomunicación, Campus Universitario, Vigo (Pontevedra) 36200, Spain. rhermida@tsc.uvigo.es 2005 American Heart Association, Inc. Hypertension is available at DOI: /01.HYP c 1060
2 Hermida et al Chronopharmacology of ASA 1061 these BP studies, all of which used ambulatory BP monitoring (ABPM) to derive primary outcome variables, are consistent; BP-lowering effect of low-dose ASA is achieved when administered at bedtime but not on awakening. On the other hand, some specific features of the 24-hour BP pattern are linked to the progressive injury of target tissues and the triggering of cardiac and cerebrovascular events. 15 Many studies show the extent of the nocturnal BP decline is deterministic of cardiovascular injury and risk. Absence of the normal 10% to 20% sleep-time BP decline (dipper pattern) is associated with elevated risk of end-organ injury, particularly to the heart (left ventricular hypertrophy and myocardial infarct), brain (stoke), and kidney (albuminuria and progression to end-stage renal failure) Previous studies have found that non-dippers may be characterized by enhanced oxidative stress. 19 Moreover, recent results have suggested that endothelium-dependent vasodilation is blunted through a decrease in NO release in non-dippers compared with patients who have dipper hypertension. 20 The antioxidative properties of ASA and its documented beneficial effects on NO production could result in a further effect on BP in non-dippers compared with dippers. In keeping with the chronopharmacological effects of ASA, this prospective randomized study investigated the comparative influence of ASA on BP in dipper and nondipper subjects with mild hypertension who received lowdose ASA at different times of the day according to their rest activity cycle and who were evaluated by 48-hour ABPM before and after 3 months of pharmacological intervention. Methods Subjects The study was conducted at the Hypertension and Vascular Risk Unit, Hospital Clínico Universitario, Santiago de Compostela, Spain, between June 2003 and February Shift workers, heavy drinkers (alcohol intake 80 g per day), smokers ( 20 cigarettes per day), and heavy exercisers were excluded, as were individuals with contraindications to the use of ASA and those with either moderate or severe arterial hypertension (grade 2 or 3; ie, BP 160/ 100 mm Hg) or secondary arterial hypertension and cardiovascular disorders, including angina, heart failure, stroke, nephropathy, and retinopathy, or previous myocardial infarction or coronary revascularization, as revealed by thorough clinical evaluation according to the standardized protocol at the unit. Inclusion criteria required a diagnosis of previously untreated grade 1 (mild) essential hypertension based on conventional BP measurements (systolic BP [SBP] between 140 and 159 mm Hg or diastolic BP [DBP] between 90 and 99 mm Hg) 21 and corroboration by ABPM at the time of recruitment. A positive diagnosis of hypertension based on ABPM required that either the diurnal mean be 135/85 mm Hg, or the nocturnal mean be 120/70 mm Hg. 22,23 With these inclusion criteria, we identified and randomized 270 untreated volunteers. Among those, 257 volunteers (98 men and 159 women; years of age) completed the study and provided all required information. The use of antihypertensive and any other medication, apart from the provided dose of ASA, was forbidden during the trial. The demographic characteristics of the participants are included in Table 1. After providing informed consent to participate in this prospective, randomized, open-label, blinded end point (PROBE), parallelgroup trial, subjects were assigned randomly to receive ASA (100 mg per day) either on awakening or at bedtime. The dose of 100 mg used in this trial corresponds with the actual lower dose commercially available in Spain within the accepted range of low dose (75 to 150 mg 24 ). Compliance was measured on the basis of tablet count and a personal interview with each volunteer. Benefits of the PROBE design and its validity compared with double-blind, placebocontrolled trials in assessing antihypertensive efficacy based on blinded ABPM measurements have been documented previously. 25 The review board on human studies at our institution approved the protocol. Blood samples were obtained in the clinic from the antecubital vein after nocturnal fasting between 8 AM and 9 AM on the same days when 48-hour ABPM was initiated, immediately before and after 3 months of timed treatment. Clinic BP measurements (6 per study visit after being seated for 5 minutes, on the same day just before starting ABPM) were always obtained by the same investigator with a validated automatic oscillometric device (HEM-737; Omron Health Care Inc.). 26 The sample size for this trial was calculated as follows. Assuming an SD of 8 mm Hg for ABPM, 14 with 41 subjects per arm, the study could have 80% power to show as significant at the 95% level changes of 5 mm Hg in ABPM between treatment groups. Assuming with the provided inclusion criteria a prevalence of non-dippers about one third of the total sample, 14,27 a minimum of 123 patients per arm would be needed. The distribution of patients who completed the study was as follows (Table 1): 80 dipper and 46 non-dipper patients received ASA on awakening; 83 dipper and 48 non-dipper patients received ASA at bedtime. ABPM Assessment The SBP, DBP, and heart rate (HR) of each participant were automatically measured every 20 minutes from 7 AM to 11 PM and every 30 minutes during the night for 48 consecutive hours with a properly calibrated SpaceLabs device (SpaceLabs Inc.). Subjects were studied by ABPM under baseline conditions, when subjects were free of medication, and again after 3 months of timed intervention with ASA. They were assessed while adhering to their usual diurnal activity (8 AM to 11 PM for most) and nocturnal sleep routine. Participants were instructed to go about their usual activities with minimal restrictions but to follow a similar schedule during the 2 days of ABPM and to avoid daytime napping. No one was hospitalized during monitoring. ABPM always began between 10 AM and 12 PM. BP series were not considered valid for analysis if 30% of the measurements were lacking, if they had missing data for 2-hour spans, or if they were collected from subjects while they were experiencing an irregular rest activity schedule or a nighttime sleep span of 6 hours or 12 hours during monitoring. Protocolcorrect data series were collected from 257 subjects. Baseline BP profiles of 13 additional subjects (7 assigned to morning treatment with ASA and 6 to bedtime treatment) could not be used for analysis because the patients failed to return for the second ABPM at the end of intervention. Actigraphy During 48-hour ABPM, each participant wore a Mini-Motion- Logger actigraph (Ambulatory Monitoring Inc.) on the dominant wrist to monitor physical activity every minute. This compact (about half the size of a wrist watch) device functions as an accelerometer. The internal clocks of the actigraph and the ABPM devices were synchronized through their respective interfaces by the same computer. The actigraphy data were used to determine the onset and offset times of diurnal activity and nocturnal sleep to accurately determine the diurnal and nocturnal BP means of each subject. The mean activity for the 5 minutes before each BP reading was then calculated for further statistical analysis on circadian variability of activity, according to previous studies on this area. 27,28 Statistical Methods Each individual s clock hour BP and HR values were first rereferenced from clock time to hours after awakening from nocturnal sleep according to the information obtained from wrist actigraphy. This transformation avoided the introduction of bias caused by differences among subjects in their sleep/activity routine. 27 BP and HR time
3 1062 Hypertension October 2005 Part II TABLE 1. Demographic and Analytical Characteristics of Subjects Investigated Variable* Aspirin on Awakening Aspirin at Bedtime P for Group Comparison Patients, n Sex, % men Age, years Height, cm Before treatment Weight, kg BMI, kg/m Waist, cm Hip, cm Clinic SBP, mm Hg Clinic DBP, mm Hg Clinic pulse pressure, mm Hg Clinic HR, bpm Non-dipper, % Hemoglobin, g/dl Glucose, mg/dl Creatinine, mg/dl Uric acid, mg/dl Cholesterol, mg/dl Triglycerides, mg/dl After treatment (in parentheses; P value from comparison with values before treatment) Weight, kg (0.481) (0.146) BMI, kg/m (0.414) (0.205) Waist, cm (0.589) (0.983) Hip, cm (0.236) (0.647) Clinic SBP, mm Hg (0.205) ( 0.001) Clinic DBP, mm Hg (0.107) ( 0.001) Clinic pulse pressure, mm Hg (0.698) ( 0.001) Clinic HR, bpm (0.102) (0.047) Non-dipper, % 35.7 (0.896) 26.7 (0.084) Hemoglobin, g/dl (0.871) (0.272) Glucose, mg/dl (0.841) (0.243) Creatinine, mg/dl (0.505) (0.082) Uric acid, mg/dl (0.945) (0.140) Cholesterol, mg/dl (0.101) (0.009) Triglycerides, mg/dl (0.644) (0.006) *All values given in mean SD. Non-dipper: 10% decline in nocturnal mean relative to the diurnal mean of BP using data sampled by ABPM for 48 consecutive hours. Values provided correspond to the average of 6 conventional BP measurements obtained for each subject at the clinic before starting ABPM. series were then edited according to conventional criteria to remove measurement errors and outliers. 29 Thus, readings with SBP 250 or 70 mm Hg, DBP 150 or 40 mm Hg, and pulse pressure (difference between SBP and DBP) 150 or 20 mm Hg were automatically discarded. For descriptive purposes, the circadian rhythm of BP, HR, and wrist activity before and after 3 months of intervention was assessed objectively by population multiplecomponent analysis. 30 The circadian rhythm parameters of midline estimating statistic of rhythm (average value of the rhythmic function fitted to the data), overall amplitude (one half the difference between the maximum and the minimum values of the best fitted curve), and orthophase (peak time, expressed as a lag from the time of awakening from nocturnal sleep) obtained for each group of patients before and after intervention were compared with a paired nonparametric test developed to assess differences in parameters derived from population multiple-components analysis. 31 Hourly BP means obtained before and after intervention were compared by t test corrected for multiple testing with the Holm procedure. 32 The daily (24-hour), diurnal, and nocturnal means of BP were further compared among groups by ANOVA. The demographic and clinical characteristics in Table 1 were compared among groups by ANOVA (quantitative variables) or nonparametric 2 test.
4 Hermida et al Chronopharmacology of ASA 1063 Results Demographic and Analytic Characteristics The baseline characteristics of the 2 groups of subjects (Table 1) were similar in age, height, weight, body mass index (BMI), waist and hip perimeters, and clinic SBP and DBP (average of the 6 morning measurements obtained just before ABPM). Moreover, there were no statistically significant changes in weight, BMI, and the waist and hip perimeters in either group after 3 months of intervention. Clinic BP measurements were reduced significantly from baseline ones (5.2 and 2.4 mm Hg in SBP and DBP; P 0.001) only in the group receiving ASA at bedtime. The serum values of glucose, creatinine, uric acid, cholesterol, triglycerides (Table 1), and other laboratory chemistry variables were comparable between the 2 treatment groups at baseline and after 3 months of intervention. Use of the low dose of 100 mg per day of ASA did not modify the baseline values of hemoglobin at any time of administration tested here (Table 1). Plasma lipids were reduced slightly after ASA at bedtime (Table 1), although the reduction would not be statistically significant if corrected for multiple testing. ABPM Characteristics The circadian variation of SBP (top) and DBP (bottom) in untreated mild hypertensive patients (irrespective of their baseline dipping status) measured by 48-hour ABPM before and after 3 months of ASA on awakening is depicted in Figure 1 (left panels). There was no statistically significantly change in the diurnal means of BP after 3 months of 100 mg per day of ASA ingested on awakening. BP slightly increased during nocturnal resting hours (Table 2). The graphs on the right in Figure 1 show the significant reduction compared with baseline of 7.2 and 4.9 mm Hg in the 24-hour mean of SBP and DBP, respectively (P 0.001), after 3 months of 100 mg per day of ASA taken at bedtime. BP was reduced homogeneously during the hours of diurnal activity and nocturnal rest. Figure 1 further indicates that the mean reduction in BP at each hourly average during the 24-hour dosing interval was statistically significant (P always 0.05 after correcting for multiple testing). A reduction in BP was observed in 94% of the patients in this group. Only 2 patients experienced a significant BP elevation after treatment. Despite the significant effect on BP, HR remained unchanged after 3 months of treatment (decrease in the 24-hour mean of 1.3 bpm; P 0.218). The circadian pattern of wrist activity was also similar before and after 3 months of therapy (P for comparison of 24-hour mean activity). Average duration of nocturnal rest determined by actigraphy was not statistically different (P 0.698) for the profiles obtained before and after intervention (Table 2). The comparison of results provided in Figure 1 indicates the lack of statistically significant differences in BP at baseline among the 2 treatment groups. After intervention, results indicate a highly significant absolute and relative reduction in BP only after ASA ingested at bedtime but not on awakening (P for SBP and DBP; Table 2). ASA Effects According to Dipping Status Figure 2 provides information on the comparison between the treatment groups of the changes in the diurnal, nocturnal, and 24-hour mean BP values after 3 months of therapy, with patients in each group divided according to their baseline dipping status. Results indicate the lack of significant effects of SBP (top) and DBP (bottom) of ASA administered on awakening in dipper (patients with 10% decline in the nocturnal relative to the diurnal BP mean using all data sampled for 48 hours) and non-dipper hypertensive patients. There was no difference in BP changes between dipper and non-dipper patients after morning dosing of ASA. Results from Figure 2 further indicate the statistically significant reduction in the 24-hour mean of SBP and DBP after ASA at bedtime. This reduction was comparable for dipper and non-dipper patients (P and for comparison of 24-hour mean reduction in SBP and DBP, respectively, between groups). The BP reduction during diurnal active hours was slightly although not significantly larger in dippers compared with non-dippers. However, the reduction in nocturnal BP mean was double in non-dippers (11.0 and 7.1 mm Hg in SBP and DBP, respectively) compared with dippers (5.5 and 3.3 mm Hg; P 0.001). Accordingly, there was a significant decrease in the nocturnal decline relative to the diurnal mean of BP (diurnal/nocturnal BP ratio) in non-dipper patients after bedtime dosing with ASA (4.0 and 4.4 for SBP and DBP; P 0.001). Among these patients, 58.3% reverted to a dipper BP pattern after treatment. Discussion Corroborating previous findings, 14 the major result from this study is that ASA selectively decreases BP as a function of the timing of its administration in relation to the rest activity cycle of each individual subject. The administration timedependent effects of ASA on BP demonstrated here are fully in agreement with conclusions found previously in clinically healthy normotensive subjects as well as in hypertensive patients using the same low dose of 100 mg per day ASA but for the much shorter time of just 1 week. 11,12 However, a higher dose of ASA (500 mg per day) showed a pressor effect even when administered before bedtime. 12 Indeed, it has been reported that NSAID may increase BP in normotensive and hypertensive subjects. 33,34 In any event, the dose of ASA regularly used to show anti-inflammatory effects is markedly larger than the dose used as anticoagulant and recommended for prevention of cardiovascular events. 35 Similar results regarding the time-dependent influence of low-dose ASA on BP were also shown in pregnant women who used 100 mg per day of ASA for most of their pregnancy, 13 as well as in a previous independent trial in patients with mild hypertension. 14 In the present study, low-dose ASA administered at bedtime not only significantly reduced the mean BP from ABPM but also conventional BP measurements. With respect to the potential mechanism(s) involved in the responsiveness of BP to ASA administered at different times according to the rest activity cycle, the effects of ASA on and -adrenergic receptors depend markedly on the circadian timing of ASA administration. 9 -Adrenoceptor blockade more effectively reduces peripheral resistance in the early morning hours than at other times of the day. 36 Moreover, a recent study exploring the administration time-dependent
5 1064 Hypertension October 2005 Part II Figure 1. Changes in the circadian pattern of SBP (top) and DBP (bottom) after aspirin (100 mg per day) administered on awakening (left) or at bedtime (right) in patients with mild hypertension sampled by 48-hour ABPM. Each graph shows the hourly means and SEs of data collected before (continuous line) and after (dashed line) 3 months of aspirin administration. Dark shading along the lower horizontal axis of the graphs represents average hours of nocturnal sleep across the patients. Nonsinusoidal-shaped curves represented around means and SEs correspond to the best-fitted waveform model determined by population multiple-component analysis. Arrows descending from upper horizontal axis point to the circadian orthophase (rhythm crest time). effects of the new gastrointestinal therapeutic system formulation of the -blocker doxazosin 37 concluded that daily ingestion of the medication at bedtime resulted in a statistically significant doubling of the amount of 24-hour mean BP reduction compared with morning dosing. Most important, ASA has been shown to provide a significant inhibition of angiotensin II dependent on the dose and circadian time of ASA administration. 10 Moreover, ASA is known to acetylate a variety of proteins, including COX-2. COX-2 inhibition has also been shown to decrease renin content and to lower BP in
6 Hermida et al Chronopharmacology of ASA 1065 TABLE 2. ABPM Characteristics of Subjects Investigated Variable* Aspirin on Awakening Aspirin at Bedtime Patients, n Before treatment P for Group Comparison Nocturnal rest, hours Diurnal mean of SBP, mm Hg Nocturnal mean of SBP, mm Hg hour mean of SBP, mm Hg Diurnal/nocturnal ratio of SBP, % Diurnal mean of DBP, mm Hg Nocturnal mean of DBP, mm Hg hour mean of DBP, mm Hg Diurnal/nocturnal ratio of DBP, % After treatment (in parentheses; P value from comparison with values before treatment) Nocturnal rest, hours (0.109) (0.698) Diurnal mean of SBP, mm Hg (0.139) ( 0.001) Nocturnal mean of SBP, mm Hg (0.101) ( 0.001) hour mean of SBP, mm Hg (0.054) ( 0.001) Diurnal/nocturnal ratio of SBP, % (0.485) (0.028) Diurnal mean of DBP, mm Hg (0.362) ( 0.001) Nocturnal mean of DBP, mm Hg (0.054) ( 0.001) hour mean of DBP, mm Hg (0.092) ( 0.001) Diurnal/nocturnal ratio of DBP, % (0.109) (0.261) Average percent reduction from baseline Diurnal mean of SBP Nocturnal mean of SBP hour mean of SBP Diurnal mean of DBP Nocturnal mean of DBP hour mean of DBP *All values given in mean SD. The diurnal/nocturnal ratio, an index of the BP dipping, is defined as the percent decline in BP during hours of nocturnal rest relative to the mean BP obtained during the hours of diurnal activity. a model of renovascular hypertension. 38 These results may be relevant inasmuch as ASA given at the end of the activity cycle could thus target the nocturnal peak of plasma renin activity while enhancing the nocturnal trough in the production of NO. 7 This hypothesis gains relevancy given the significantly enhanced effect of ASA in reducing the nocturnal mean of BP in non-dipper hypertensive patients (Figure 2), who are characterized by a decrease in NO release compared with dipper patients. 20 The potential added impact on NO or plasma renin activity attributable to the timed administration of low-dose ASA deserves further investigation. The mechanisms underlying the loss of the nocturnal decline in BP are still unclear. Nonetheless, the extent of the nocturnal decline in BP in hypertension seems to be of clinical importance. Verdecchia et al 16 showed that after an average follow-up period of 3.2 years, non-dipper hypertensive patients experienced nearly 3 as many adverse cardiovascular events as dippers. More recently, Staessen et al, 17 summarizing results from the Syst-Eur trial, in which nitrendipine was dosed at bedtime, reported that non-dippers experienced a greater incidence of stroke and myocardial infarction than the group of persons who had a normal dipping pattern after treatment. Results of this trial also suggested that nighttime BP was the best predictor of risk. A recent evaluation of the data from the Ohasama Study indicated that after an average follow-up of 9.2 years, a 5% decrease in the decline of nocturnal SBP in hypertensive patients was associated with a 31% increased risk of cardiovascular mortality. 18 The potential reduction in cardiovascular risk associated with the normalization of the circadian variability of BP (converting a non-dipper to dipper pattern) has not yet been clearly established. Apart from the Syst-Eur trial mentioned above, results from the Heart Outcomes Prevention Evaluation (HOPE) substudy, in which patients were evaluated by ABPM, indicated a significant BP reduction, mainly during hours of nighttime sleep. 39 The authors suggested that the
7 1066 Hypertension October 2005 Part II Figure 2. Changes in diurnal, nocturnal, and 24-hour means of SBP (top) and DBP (bottom) after aspirin (100 mg per day) administered on awakening or at bedtime in dipper and non-dipper patients with mild hypertension studied by 48-hour ABPM. P values are shown for comparison between groups of patients by ANOVA. beneficial effects on cardiovascular morbidity and mortality in the HOPE study may be related to the 8% increase in the diurnal/nocturnal ratio of BP seen after ramipril was administered at bedtime. The potential advantages in terms of cardiovascular risk reduction from bedtime administration of ASA, mainly in non-dipper patients, deserve further prospective investigation. Results from this prospective trial refer exclusively to untreated patients with newly diagnosed mild hypertension. Other studies have shown no influence of low-dose ASA on BP in hypertensive patients under pharmacological therapy, 40,41 yet the time of ingestion of ASA (presumably morning 27 ) has not been reported. Whether or not ASA enhances the effects of antihypertensive medication or if such a possible influence is circadian time dependent are further issues of clinical interest that should be addressed in future research. Regarding other relevant issues related to ASA administered at different times of the day, compliance was not different in this trial between awakening and bedtime dose.
8 Hermida et al Chronopharmacology of ASA 1067 The number of patients who concluded the study was similar at both treatment times, and no patients abandoned the trial because of secondary effects. With respect to tolerability and potential side effects, a previous endoscopic trial on volunteers who took high-dose ASA (1300 mg) at different times on separate study days has shown that the evening dose compared with the morning dose produced 37% fewer gastric hemorrhagic lesions. 42 Although low-dose ASA would be associated generally with lower potential risks compared with higher doses, previous studies have concluded that nighttime administration of ASA is better tolerated than morning administration. 42 Perspectives The results from this prospective trial in untreated patients with mild hypertension corroborate previous findings on the administration time-dependent influence of low-dose ASA on BP. These beneficial effects are significantly larger in nondipper compared with dipper patients, mainly in the control of nocturnal BP, a result that may be related to the documented increase in NO release from vascular endothelium attributable to ASA. Apart from the documented benefits of ASA in the secondary prevention of cardiovascular disease, results indicate that the timed administration of low-dose ASA with respect to the rest activity cycle of each individual patient could provide a valuable approach for BP control of patients with mild essential hypertension. Apart from the BP-lowering effect, low-dose ASA administered at bedtime, but not on awakening, has also been shown to be protective against preeclampsia, gestational hypertension, intrauterine growth retardation, and preterm delivery in high-risk pregnant women. 13 Whether or not low-dose ASA administered at the end of the activity cycle is able to provide further cardiovascular protection in hypertensive patients beyond documented findings deserves prospective investigation. Acknowledgments This research was supported in part by grants from Xunta de Galicia (PGIDIT03-PXIB-32201PR), Química Farmacéutica Bayer, and Vicerrectorado de Investigación, University of Vigo. References 1. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Dave G, Forni L. Clinical pharmacology of platelet cyclo-oxygenase inhibition. Circulation. 1985;72: Wu R, Lamontagne D, de Champlain J. Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation. 2002;105: Wu R, Laplante MA, de Champlain J. Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in rats. J Hypertens. 2004;22: Grosser N, Schroder H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cgmp pathway. Arterioscler Thromb Vasc Biol. 2003;23: Taubert D, Berkels R, Grosser N, Schroder H, Grundemann D, Schomig E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol. 2004;143: Kanabrocki EL, Murray D, Hermida RC, Scott GS, Bremner WF, Ryan MD, Ayala DE, Third JL, Shirazi P, Nemchausky BA, Hooper DC. Circadian variation in oxidative stress markers in healthy and type II diabetic men. Chronobiol Int. 2002;19: Kanabrocki EL, George M, Hermida RC, Messmore HL, Ryan MD, Ayala DE, Hoppensteadt DA, Fareed J, Bremmer FW, Third JL, Shirazi P, Nemchausky BA. Day-night variations in blood levels of nitric oxide, T-TFPI, and E-selectin. Clin Appl Thromb Hemost. 2001;7: Angeli A, Gatti G, Masera R. Chronobiology of the hypothalamicpituitary-adrenal and renin-angiotensin-aldosterone systems. In: Touitou Y, Haus E, eds. Biologic Rhythms in Clinical and Laboratory Medicine. Berlin, Germany: Springer-Verlag; 1992: Cornélissen G, Halberg F, Prikryl P, Dankova E, Siegelova J, Dusek J; International Womb-To-Tomb Chronome Study Group. Prophylactic aspirin treatment: the merits of timing. J Am Med Assoc. 1991;266: Abacioglu N. Effects of drugs and electroshock on blood angiotensin II concentrations. Ankara University, Department of Pharmacology, PhD. Dissertation; Hermida RC, Fernández JR, Ayala DE, Iglesias M, Halberg F. Timedependent effects of ASA administration on blood pressure in healthy subjects. Chronobiologia. 1994;21: Hermida RC, Fernández JR, Ayala DE, Mojón A, Iglesias M. Influence of aspirin usage on blood pressure. Dose and administration-time dependencies. Chronobiol Int. 1997;14: Hermida RC, Ayala DE, Iglesias M. Administration-time dependent influence of aspirin on blood pressure in pregnant women. Hypertension. 2003;41: Hermida RC, Ayala DE, Calvo C, López JE, Fernández JR, Mojón A, Domínguez MJ, Covelo M. Administration-time dependent effects of aspirin on blood pressure in untreated hypertensive patients. Hypertension. 2003;41: Hermida RC, Smolensky MH. Chronotherapy of hypertension. Curr Opin Nephrol Hypertens. 2004;13: Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistell M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1994;24: Staessen JA, Thijs L, Fagard R, O Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. J Am Med Assoc. 1999;282: Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama Study. J Hypertens. 2002;20: Pierdomenico SD, Costantini F, Bucci A, De Cesare D, Bucciarelli T, Cuccurullo F, Mezzetti A. Blunted nocturnal fall in blood pressure and oxidative stress in men and women with essential hypertension. Am J Hypertens. 1999;12: Higashi Y, Nakagawa K, Kimura M, Noma K, Hara K, Sasaki S, Goto C, Oshima T, Chayama K, Yoshizumi M. Circadian variation of blood pressure and endothelial function in patients with essential hypertension: a comparison of dippers and non-dippers. J Am Coll Cardiol. 2002;40: Guidelines Committee European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2003;21: O Brien A, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21: Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: Blood pressure measurement in humans. Hypertension. 2005;45: Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324: Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens. 2003;21: Anwar YA, Giacco S, McCabe EJ, Tendler BE, White WB. Evaluation of the efficacy of the Omron HEM-737 Intellisense device for use on adults according to the recommendations of the Association for the
9 1068 Hypertension October 2005 Part II Advancement of Medical Instrumentation. Blood Press Monit. 1998;3: Hermida RC, Calvo C, Ayala DE, Mojón A, López JE. Relationship between physical activity and blood pressure in dipper and nondipper hypertensive patients. J Hypertens. 2002;20: Mansoor GA, White WB, McCabe EJ, Giacco S. The relationship of electronically monitored physical activity to blood pressure, heart rate, and the circadian blood pressure profile. Am J Hypertens. 2000;13: Staessen J, Fagard R, Lijnen P, Thijs L, Vaa Hoof R, Amery A. Ambulatory blood pressure monitoring in clinical trials. J Hypertens. 1991; 9(suppl 1):s13 s Fernández JR, Hermida RC. Inferential statistical method for analysis of nonsinusoidal hybrid time series with unequidistant observations. Chronobiol Int. 1998;15: Fernández JR, Mojón A, Hermida RC. Comparison of parameters from rhythmometric models with multiple components on hybrid data. Chronobiol Int. 2004;21: Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6: Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153: Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121: Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991;325: Panza JA, Epstein SE, Quyyumi AA. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med. 1991;325: Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Fontao MJ, López JE. Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects. Chronobiol Int. 2004;21: Wang JL, Cheng HF, Harris RC. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension. 1999;34: Svensson P, de Faire U, Sleight P, Yusuf S, Östergren J. Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension. 2001;38:e28 e Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler SA. Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens. 1999;12: Avanzini F, Palumbo G, Alli C, Roncaglioni MC, Ronchi E, Cristifari M, Capra A, Rossi S, Nosotti L, Costantini C, Pietrofeso R; Collaborative Group of the Primary Prevention Project (PPP) Hypertension Study. Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Am J Hypertens. 2000;13: Moore JG, Goo RH. Day and night aspirin-induced gastric mucosal damage and protection by ranitidine in man. Chronobiol Int. 1987;4:
Aspirin Administered at Bedtime, But Not on Awakening, Has an Effect on Ambulatory Blood Pressure in Hypertensive Patients
Journal of the American College of Cardiology Vol. 46, No. 6, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.08.071
More informationEvaluation of the Extent and Duration of the ABPM Effect in Hypertensive Patients
Journal of the American College of Cardiology Vol. 40, No. 4, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02011-9
More informationHypertension has been defined as resistant to treatment, or
Chronotherapy in Resistant Hypertension Chronotherapy Improves Blood Pressure Control and Reverts the Nondipper Pattern in Patients With Resistant Hypertension Ramón C. Hermida, Diana E. Ayala, José R.
More informationThere is an extensive literature on the effects of acetylsalicylic
Administration Time Dependent Effects of Aspirin on Blood Pressure in Untreated Hypertensive Patients Ramón C. Hermida, Diana E. Ayala, Carlos Calvo, José E. López, José R. Fernández, Artemio Mojón, María
More informationOptimal timing for antihypertensive dosing: focus on valsartan
REVIEW Optimal timing for antihypertensive dosing: focus on valsartan Ramón C Hermida Diana E Ayala Carlos Calvo Bioengineering & Chronobiology Laboratories, University of Vigo, Campus Universitario, Vigo,
More informationANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION*
Progress in Clinical Medicine 1 ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Keishi ABE** Asian Med. J. 44(2): 83 90, 2001 Abstract: J-MUBA was a large-scale clinical
More informationChronotherapy. Ramón C. Hermida, Diana E. Ayala
Chronotherapy Chronotherapy With the Angiotensin-Converting Enzyme Inhibitor Ramipril in Essential Hypertension Improved Blood Pressure Control With Bedtime Dosing Ramón C. Hermida, Diana E. Ayala Abstract
More informationAmbulatory Blood Pressure Control With Bedtime Aspirin Administration in Subjects With Prehypertension
articles nature publishing group Ambulatory Blood Pressure Control With Bedtime Aspirin Administration in Subjects With Prehypertension Ramón C. Hermida 1, Diana E. Ayala 1, Artemio Mojón 1 and José R.
More informationAGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK. Michael Smolensky, Ph.D. The University of Texas Austin & Houston
AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK Michael Smolensky, Ph.D. The University of Texas Austin & Houston Disclosures Partner: Circadian Ambulatory Diagnostics Consultant: Spot On Sciences
More informationThe morning pressor surge is an abrupt increase in blood
Original Articles Prognostic Significance for Stroke of a Morning Pressor Surge and a Nocturnal Blood Pressure Decline The Ohasama Study Hirohito Metoki, Takayoshi Ohkubo, Masahiro Kikuya, Kei Asayama,
More informationBlood Pressure Variability and Its Management in Hypertensive Patients
Korean J Fam Med. 2012;33:330-335 http://dx.doi.org/10.4082/kjfm.2012.33.6.330 Blood Pressure Variability and Its Management in Hypertensive Patients Review Hee-Jeong Choi* Department of Family Medicine,
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationComparison of arbitrary definitions of circadian time periods with those determined by wrist actigraphy in analysis of ABPM data
Journal of Human Hypertension (1999) 13, 449 453 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Comparison of arbitrary definitions of
More informationSleep-time BP: prognostic marker of type 2 diabetes and therapeutic target for prevention
Diabetologia (2016) 59:244 254 DOI 10.1007/s00125-015-3748-8 ARTICLE Sleep-time BP: prognostic marker of type 2 diabetes and therapeutic target for prevention Ramón C. Hermida 1 & Diana E. Ayala 1 & Artemio
More informationThe hypertensive effects of the renin-angiotensin
Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point
More informationINFLUENCE OF GENDER, TRAINING AND CIRCADIAN TIME OF TESTING IN THE CARDIOVASCULAR RESPONSE TO STRESS TESTS
1 of 4 INFLUENCE OF GENDER, TRAINING AND CIRCADIAN TIME OF TESTING IN THE CARDIOVASCULAR RESPONSE TO STRESS TESTS I. Alonso, J. R. Fernández, R.C. Hermida, A. Mojón Bioengineering & Chronobiology Labs.
More informationMorning Hypertension: A Pitfall of Current Hypertensive Management
Review Article Hypertension: A Pitfall of Current Hypertensive Management JMAJ 48(5): 234 240, 2005 Kazuomi Kario* 1 Abstract has recently attracted more attention because of the close relation between
More informationa Hypertension and Cardiovascular Rehabilitation Unit, Faculty of Medicine, Received 2 June 2008 Revised 1 July 2008 Accepted 9 July 2008
Original article 325 Prognostic significance of ambulatory blood pressure in hypertensive patients with history of cardiovascular disease Robert H. Fagard a, Lutgarde Thijs a, Jan A. Staessen a, Denis
More informationBedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial
DOI 10.1007/s00125-015-3749-7 ARTICLE Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial Ramón C. Hermida 1 & Diana E. Ayala 1 &
More informationChapter-V. Summary, Conclusions and Recommendations
Summary, Conclusions and Recommendations INTRODUCTION The work included in this thesis entitled, Circadian heart rate and blood pressure variability in apparently healthy subjects using ABPM has been divided
More informationProtocol. Automated Ambulatory Blood Pressure Monitoring for the Diagnosis of Hypertension in Patients with Elevated Office Blood Pressure
Automated Ambulatory Blood Monitoring for the Diagnosis of Hypertension in Patients with Elevated Office Blood (10102) Medical Benefit Effective Date: 07/01/14 Next Review Date: 03/15 Preauthorization
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationDIURNAL VARIATIONS IN BLOOD PRESSURE AND THEIR RELATION WITH CAROTID ARTERY INTIMA-MEDIA THICKENING
DIURNAL VARIATIONS IN BLOOD PRESSURE AND THEIR RELATION WITH CAROTID ARTERY INTIMA-MEDIA THICKENING Sh Narooei (1), B Soroor (2), F Zaker (3) Abstract INTRODUCTION: Hypertension is a very common cardiovascular
More informationReceived 24 February 2015 Revised 29 April 2015 Accepted 20 May 2015
Original article 1 Clinical practice of ambulatory versus home blood pressure monitoring in hypertensive patients Jorge A. Paolasso, Florencia Crespo, Viviana Arias, Eduardo A. Moreyra, Ariel Volmaro,
More informationand bias, which are known to be present in self-home and in professional office BP measurements taken using the auscultatory technique [7].
Devices and technology 37 Validation of the A&D UM-11 professional hybrid device for office blood pressure measurement according to the International Protocol George S. Stergiou, Periklis P. Giovas, Charilaos
More informationAmbulatory Blood Pressure Monitoring Clinical Practice Recommendations
Acta Medica Marisiensis 2016;62(3):350-355 DOI: 10.1515/amma-2016-0038 UPDATE Ambulatory Blood Pressure Monitoring Clinical Practice Recommendations Mako Katalin *, Ureche Corina, Jeremias Zsuzsanna University
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationValidation of the SEJOY BP-1307 upper arm blood pressure monitor for home. blood pressure monitoring according to the European Society of Hypertension
Validation of the SEJOY BP-1307 upper arm blood pressure monitor for home blood pressure monitoring according to the European Society of Hypertension International Protocol revision 2010 Short title: Validation
More informationAlgorithm for Sleep/Wake Identification From Actigraphy
Algorithm for Sleep/Wake Identification From Actigraphy Crespo C 1, Aboy M 1, Fernández JR 2, Mojón A 2 1 Oregon Institute of Technology (USA), 2 University of Vigo (Spain) cristina.crespo@oit.edu Abstract.
More informationAmbulatory Blood Pressure and Prognosis
Ambulatory Blood Pressure and Prognosis Daytime and Nighttime Blood Pressure as Predictors of Death and Cause-Specific Cardiovascular Events in Hypertension Robert H. Fagard, Hilde Celis, Lutgarde Thijs,
More informationAJH 1999;12: Downloaded from by guest on 15 December 2018
AJH 1999;12:806 814 Differential Effects of Morning and Evening Dosing of Nisoldipine ER on Circadian Blood Pressure and Heart Rate William B. White, George A. Mansoor, Thomas G. Pickering, Donald G. Vidt,
More informationData Alert #2... Bi o l o g y Work i n g Gro u p. Subject: HOPE: New validation for the importance of tissue ACE inhibition
Vascular Bi o l o g y Work i n g Gro u p c/o Medical Education Consultants, In c. 25 Sy l van Road South, We s t p o rt, CT 06880 Chairman: Carl J. Pepine, MD Professor and Chief Division of Cardiovascular
More informationCopyright Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Devices and technology 57 Comparison of wrist-type and arm-type 24-h blood pressure monitoring devices for ambulatory use Takahiro Komori a, Kazuo Eguchi a, Satoshi Hoshide a, Bryan Williams b and Kazuomi
More informationPrognostic Value of Different Indices of Blood Pressure Variability in Hypertensive Patients
articles nature publishing group Prognostic Value of Different Indices of Blood Pressure Variability in Hypertensive Patients Sante D. Pierdomenico 1,2, Marta Di Nicola 3, Anna L. Esposito 3, Rocco Di
More informationChronic kidney disease (CKD) is a global public health
Clinical Trial: African American Study of Kidney Disease A Trial of 2 Strategies to Reduce Nocturnal Blood Pressure in Blacks With Chronic Kidney Disease Mahboob Rahman, Tom Greene, Robert A. Phillips,
More informationTime of day for exercise on blood pressure reduction in dipping and nondipping hypertension
(2005) 19, 597 605 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE on blood pressure reduction in dipping and nondipping hypertension S Park,
More informationPrognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice
(2005) 19, 801 807 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured in the office, at home and
More informationORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY. Introduction. Patients and Methods
Vol. 2, Issue 1, pages 31-36 ORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY By Alejandro de la Sierra, MD Luis M. Ruilope, MD Hypertension Units, Hospital Clinico, Barcelona & Hospital 12 de Octubre,
More informationHome blood pressure measurement is reportedly more
Day-by-Day Variability of Blood Pressure and Heart Rate at Home as a Novel Predictor of Prognosis The Ohasama Study Masahiro Kikuya, Takayoshi Ohkubo, Hirohito Metoki, Kei Asayama, Azusa Hara, Taku Obara,
More informationTHE NEW ARMENIAN MEDICAL JOURNAL DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA)
THE NEW ARMENIAN MEDICAL JOURNAL Vol.5 (2011), Nо 2, p.29-34 DISTRIBUTION, AWARENESS, TREATMENT, AND CONTROL OF ARTERIAL HYPERTENSION IN YEREVAN (ARMENIA) Zelveian P.H. 1, 2, Podosyan G.A. 2 1 Institute
More informationThe incidence of transient myocardial ischemia,
AJH 1999;12:50S 55S Heart Rate and the Rate-Pressure Product as Determinants of Cardiovascular Risk in Patients With Hypertension William B. White Inability to supply oxygen to the myocardium when demand
More informationNocturnal Hypertension or Nondipping: Which Is Better Associated With the Cardiovascular Risk Profile?
Original Article Nocturnal Hypertension or Nondipping: Which Is Better Associated With the Cardiovascular Risk Profile? Alejandro de la Sierra, 1 Manuel Gorostidi, 2 José R. Banegas, 3 Julián Segura, 4
More informationUse and Interpretation of Home Blood Pressure Monitoring
Use and Interpretation of Home Blood Pressure Monitoring BLOOD PRESSURE in year 2015 PARAMETERS TODAY Gianfranco Parati University of Milano-Bicocca & Ospedale S.Luca, IRCCS, Istituto Auxologico Italiano
More informationImportance of Ambulatory Blood Pressure Monitoring in Adolescents
Importance of Ambulatory Blood Pressure Monitoring in Adolescents Josep Redon, MD, PhD, FAHA Internal Medicine Hospital Clinico Universitario de Valencia University of Valencia CIBERObn Instituto de Salud
More informationUse of ambulatory and home blood pressure (BP) measurements
Long-Term Risk of Mortality Associated With Selective and Combined Elevation in Office, Home, and Ambulatory Blood Pressure Giuseppe Mancia, Rita Facchetti, Michele Bombelli, Guido Grassi, Roberto Sega
More informationWhite coat and masked hypertension
White coat and masked hypertension Conflict of interest Support from Spacelabs, Microlife. Honoraria from Novartis, Elpen, Boeringer-Ingelheim, CANA, Lilly, MSD, Sanofi, Menarini, Ciezi, Astra-Zeneca.
More informationInsulin resistance influences 24h heart rate and blood pressure variabilities and cardiovascular autonomic modulation in normotensive healthy adults
Insulin resistance influences 24h heart rate and blood pressure variabilities and cardiovascular autonomic modulation in normotensive healthy adults Ochoa JE 1, Correa M 2, Valencia AM 2, Gallo J 2, McEwen
More informationCircadian Variation of Blood Pressure and Endothelial Function in Patients With Essential Hypertension: A Comparison of Dippers and Non-Dippers
Journal of the American College of Cardiology Vol. 40, No. 11, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02535-4
More informationUniversity of Padova, Padua, Italy, and HARVEST Study Group, Italy
University of Padova, Padua, Italy, and HARVEST Study Group, Italy ISOLATED SYSTOLIC HYPERTENSION IN THE YOUNG DOES NOT IMPLY AN INCREASED RISK OF FUTURE HYPERTENSION NEEDING TREATMENT Mos L, Saladini
More informationBRIEF COMMUNICATIONS. KEY WORDS: Ambulatory blood pressure monitoring, placebo effect, antihypertensive drug trials.
AJH 1995; 8:311-315 BRIEF COMMUNICATIONS Lack of Placebo Effect on Ambulatory Blood Pressure Giuseppe Mancia, Stefano Omboni, Gianfranco Parati, Antonella Ravogli, Alessandra Villani, and Alberto Zanchetti
More informationPrognostic significance of blood pressure measured on rising
(2001) 15, 413 417 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured on rising P Gosse, C Cipriano,
More informationNormal Ambulatory Blood Pressure: A Clinical-Practice- Based Analysis of Recent American Heart Association Recommendations
The American Journal of Medicine (2006) 119, 69.e13-69.e18 CLINICAL RESEARCH STUDY Normal Ambulatory Blood Pressure: A Clinical-Practice- Based Analysis of Recent American Heart Association Recommendations
More informationAbnormalities in chronic kidney disease of ambulatory blood pressure 24 h patterning and normalization by bedtime hypertension chronotherapy
Nephrol Dial Transplant (2014) 29: 1160 1167 doi: 10.1093/ndt/gft285 Advance Access publication 5 September 2013 Abnormalities in chronic kidney disease of ambulatory blood pressure 24 h patterning and
More informationWithin-Home Blood Pressure Variability on a Single Occasion Has Clinical Significance
Published online: May 12, 2016 2235 8676/16/0041 0038$39.50/0 Mini-Review Within-Home Blood Pressure Variability on a Single Occasion Has Seiichi Shibasaki a, b Satoshi Hoshide b Kazuomi Kario b a Department
More informationBedtime Dosing of Antihypertensive Medications Reduces Cardiovascular Risk in CKD
Bedtime Dosing of Antihypertensive Medications Reduces Cardiovascular Risk in CKD Ramón C. Hermida, Diana E. Ayala, Artemio Mojón, and José R. Fernández Bioengineering and Chronobiology Laboratories, University
More informationThe magnitude and duration of ambulatory blood pressure reduction following acute exercise
Journal of Human Hypertension (1999) 13, 361 366 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE The magnitude and duration of ambulatory
More informationThe Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction
The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction Cardiovascular Center, Korea University Guro Hospital 2007. 4. 20 Seung-Woon Rha, MD, PhD Introduction 1.
More informationAutomated Ambulatory Blood Pressure Monitoring for the Diagnosis of Hypertension in Patients with Elevated Office Blood Pressure
Automated Ambulatory Blood Pressure Monitoring for the Diagnosis of Hypertension in Patients with Elevated Office Blood Pressure Policy Number: 1.01.02 Last Review: 9/2014 Origination: 1/1989 Next Review:
More information47 Hypertension in Elderly
47 Hypertension in Elderly YOU DO NOT HEAL OLD AGE; YOU PROTECT IT; YOU PROMOTE IT; YOU EXTEND IT Sir James Sterling Ross Abstract: The prevalence of hypertension rises with age and the complications secondary
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Ambulatory Blood Pressure Monitoring Page 1 of 14 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Ambulatory Blood Pressure Monitoring Professional Institutional
More informationAssessing Blood Pressure for Clinical Research: Pearls & Pitfalls
Assessing Blood Pressure for Clinical Research: Pearls & Pitfalls Anthony J. Viera, MD, MPH, FAHA Department of Family Medicine Hypertension Research Program UNC School of Medicine Objectives Review limitations
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More informationJournal of Hypertension 2004, 22: a Hypertension and Cardiovascular Rehabilitation Unit, Catholic University of
Original article 81 Relationship between ambulatory blood pressure and followup clinic blood pressure in elderly patients with systolic hypertension Robert H. Fagard a, Jan A. Staessen a, Lutgarde Thijs
More informationHow do we diagnose hypertension today? Presentation Subtitle
How do we diagnose hypertension today? Presentation Subtitle Renata Cífková Case 1 JM, a 64-year-old lady referred to our center because of undesirable effects of her antihypertensive medication Personal
More informationORIGINAL INVESTIGATION. Prognosis of Isolated Systolic and Isolated Diastolic Hypertension as Assessed by Self-Measurement of Blood Pressure at Home
Prognosis of Isolated Systolic and Isolated Diastolic Hypertension as Assessed by Self-Measurement of Blood Pressure at Home The Ohasama Study ORIGINAL INVESTIGATION Atsushi Hozawa, MD; Takayoshi Ohkubo,
More informationHow well do office and exercise blood pressures predict sustained hypertension? A Dundee Step Test Study
(2000) 14, 429 433 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE How well do office and exercise blood pressures predict sustained hypertension?
More informationHome blood pressure (BP) measurement has been reported
Prognostic Value of the Variability in Home-Measured Blood Pressure and Heart Rate The Finn-Home Study Jouni K. Johansson, Teemu J. Niiranen, Pauli J. Puukka, Antti M. Jula Abstract The objective of the
More informationThe role of physical activity in the prevention and management of hypertension and obesity
The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity
More informationTwenty-Four Hour Blood Pressure Profile in Subjects with Different Subtypes of Primary Aldosteronism
Physiol. Res. 50: 51-57, 2001 Twenty-Four Hour Blood Pressure Profile in Subjects with Different Subtypes of Primary Aldosteronism T. ZELINKA, J. WIDIMSKÝ Third Medical Department, First Medical School
More informationSTATE OF THE ART BP ASSESSMENT
STATE OF THE ART BP ASSESSMENT PROFESSOR MOLECULAR PHARMACOLOGY CONWAY INSTITUE UNIVERSITY COLLEGE DUBLIN CO-CHAIRMAN BLOOD PRESCSURE MANAGEMENT IN LOW RESOURCE SETTINGS CENTRE FOR INTERNATIONAL HUMANITARIAN
More informationAsleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention
European Heart Journal (2018) 0, 1 14 doi:101093/eurheartj/ehy475 CLINICAL RESEARCH Hypertension Asleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention
More informationCircadian Variation in Blood Pressure: Dipper or Nondipper. Pierre Larochelle, MD, PhD
Reviews Circadian Variation in Blood Pressure: Dipper or Nondipper Pierre Larochelle, MD, PhD Awareness of an increased incidence of cardiovascular events shortly after awakening has heightened interest
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationThe Evolution To Treatment Of Hypertension With Advanced Formulation
The Evolution To Treatment Of Hypertension With Advanced Formulation Dr. Donald Ang MBChB (UK) FRCP (Edin) MD (UK) CCST Cardiology (UK) FESC (Europe) Consultant Cardiologist Island Hospital Penang High
More informationAn Observational Study: Ambulatory Blood Pressure Monitoring after Percutaneous Transluminal Coronary Angioplasty
THIEME Original Article 17 An Observational Study: Ambulatory Blood Pressure Monitoring after Percutaneous Transluminal Coronary Angioplasty Gopi Krishna Kenchi 1 Sunisha Gajula 2 Malleshwar Rao Dangati
More informationThis article will focus on the role of the following in BP management and their prognostic significance:
CARDIOVASCULAR DISORDERS UNIT NO. 2 HOME BLOOD PRESSURE MONITORING, BLOOD PRESSURE VARIABILITY AND MORNING BLOOD PRESSURE SURGE Dr Rohit Khurana, Dr Lucy Priestner ABSTRACT Hypertension is a common chronic
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationDr Diana R Holdright. MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION.
Dr Diana R Holdright MD, FRCP, FESC, FACC, MBBS, DA, BSc. Consultant Cardiologist HYPERTENSION www.drholdright.co.uk Blood pressure is the pressure exerted on the walls of the arteries when the heart pumps;
More informationArterial blood pressure (BP) increases with
AJH 1998;11:909 913 ORIGINAL CONTRIBUTIONS Estradiol-17 Reduces Blood Pressure and Restores the Normal Amplitude of the Circadian Blood Pressure Rhythm in Postmenopausal Hypertension Giuseppe Mercuro,
More informationAmbulatory blood pressure (ABP) may be normal in
Response to Antihypertensive Therapy in Older Patients With Sustained and Nonsustained Systolic Hypertension Robert H. Fagard, MD; Jan A. Staessen, MD; Lutgarde Thijs, BSc; Jerzy Gasowski, MD; Christopher
More informationHome blood pressure measurement with oscillometric upper-arm devices
REVIEW Home blood pressure measurement with oscillometric upper-arm devices R.L. Braam, Th. Thien *# Department of Internal Medicine, University Medical Centre St Radboud, PO Box 9101, 6500 HB Nijmegen,
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationHypertension is common among patients with chronic
Hemodialysis Blood Pressure and Mortality Among Hemodialysis Patients Rajiv Agarwal Abstract Blood pressure measured before and after dialysis does not agree well with those recorded outside the dialysis
More informationTitle: Angiotensin II Receptor Blockers: A Comparative Effectiveness Review
Title: Angiotensin II Receptor Blockers: A Comparative Effectiveness Review Date: 10 April 2008 Context and policy issues: Angiotensin II receptor blockers (ARB s) are a class of drugs that affect the
More informationNIH Public Access Author Manuscript J Hum Hypertens. Author manuscript; available in PMC 2011 May 1.
NIH Public Access Author Manuscript Published in final edited form as: J Hum Hypertens. 2010 November ; 24(11): 749 754. doi:10.1038/jhh.2010.8. Long-Term Reproducibility of Ambulatory Blood Pressure is
More information1. Department of Gynecology and Obstetrics, St. Joseph's Hospital Berlin Tempelhof, Germany
Page 1 of 9 Validation of the TONOPORT VI ambulatory blood pressure monitor, according to the European Society of Hypertension International Protocol revision 2010 Michael Abou-Dakn 1, Cornelius Döhmen
More informationOverview of the outcome trials in older patients with isolated systolic hypertension
Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated
More informationJournal of the American College of Cardiology Vol. 46, No. 3, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 3, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.070
More informationAspirin has perhaps the broadest spectrum
AJH 1999;12:784 789 Effect of Aspirin on Blood Pressure in Hypertensive Patients Taking Enalapril or Losartan James J. Nawarskas, Raymond R. Townsend, Michael D. Cirigliano, and Sarah A. Spinler The ability
More informationValidation of the OMRON 705 IT blood pressure measuring device according to the International Protocol of the European Society of Hypertension
Validation of the OMRON 705 IT blood pressure measuring device according to the International Protocol of the European Society of Hypertension M. EL ASSAAD, J. TOPOUCHIAN, G. LABAKI, R. ASMAR L Institut
More informationSUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics
Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics
More informationMEDICAL POLICY SUBJECT: AUTOMATED AMBULATORY BLOOD PRESSURE MONITORING
MEDICAL POLICY SUBJECT: AUTOMATED AMBULATORY 02/19/09 PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationProtocol. Automated Ambulatory Blood Pressure Monitoring for the Diagnosis of Hypertension in Patients With Elevated Office Blood Pressure
Automated Ambulatory Blood Monitoring for the Diagnosis of Hypertension in Patients With Elevated Office Blood (10102) Medical Benefit Effective Date: 07/01/14 Next Review Date: 03/18 Preauthorization
More informationChronopharmacotherapy of Hypertension: Time-dependent effects of treatment on blood pressure
18 Review Article Chronopharmacotherapy of Hypertension: Time-dependent effects of treatment on blood pressure Suresh Rewar 1 *, Bansal BK 1, Singh CJ 2, Sharma AK 2 1 Department of pharmaceutics, Arya
More informationAmbulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease. Rajiv Agarwal, MD
Ambulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease Rajiv Agarwal, MD Summary: Hypertension is an important risk factor for adverse cardiovascular and renal outcomes, particularly
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
Anand IS,, 2014; Volume 3(3): 178-187 INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE EFFECT OF NEBIVOLOL AND METOPROLOL ON PLATELET ACTIVATION IN HYPERTENSIVE PATIENTS ANAND IS, PATEL
More informationORIGINAL INVESTIGATION. Blunted Heart Rate Dip During Sleep and All-Cause Mortality. clinical practice and in hypertension
ORIGINAL INVESTIGATION Blunted Heart Rate Dip During Sleep and All-Cause Mortality Iddo Z. Ben-Dov, MD; Jeremy D. Kark, MD; Drori Ben-Ishay, MD; Judith Mekler, MSc; Liora Ben-Arie; Michael Bursztyn, MD
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationBLOOD PRESSURE MEASUREMENT HOME BASED OR OFFICE BP MONITORING WHICH, HOW AND WHEN?
BLOOD PRESSURE MEASUREMENT HOME BASED OR OFFICE BP MONITORING WHICH, HOW AND WHEN? DECLARATION OF INTEREST Medical Director and Chairman, Advisory Board dabl Ltd., Dublin, Ireland. BLOOD PRESSURE MEASUREMENT
More informationHypertension is a common medical disorder, affecting. Is Resistant Hypertension Really Resistant? Mark A. Brown, Megan L. Buddle, and Allison Martin
AJH 2001; 14:1263 1269 Is Resistant Hypertension Really Resistant? Mark A. Brown, Megan L. Buddle, and Allison Martin Background: Managing resistant hypertension is difficult and mostly involves expensive
More information